BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32532924)

  • 21. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.
    Xie X; Zhao X; Liu Y; Young CY; Tindall DJ; Slawin KM; Spencer DM
    Hum Gene Ther; 2001 Mar; 12(5):549-61. PubMed ID: 11268287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
    Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
    J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.
    Song H; Hobbs RF; Vajravelu R; Huso DL; Esaias C; Apostolidis C; Morgenstern A; Sgouros G
    Cancer Res; 2009 Dec; 69(23):8941-8. PubMed ID: 19920193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells.
    Kollara A; Diamandis EP; Brown TJ
    J Steroid Biochem Mol Biol; 2003 Apr; 84(5):493-502. PubMed ID: 12767274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
    Väisänen V; Peltola MT; Lilja H; Nurmi M; Pettersson K
    Anal Chem; 2006 Nov; 78(22):7809-15. PubMed ID: 17105175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
    Kratochwil C; Bruchertseifer F; Rathke H; Hohenfellner M; Giesel FL; Haberkorn U; Morgenstern A
    J Nucl Med; 2018 May; 59(5):795-802. PubMed ID: 29326358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.
    Nam RK; Zhang WW; Klotz LH; Trachtenberg J; Jewett MA; Sweet J; Toi A; Teahan S; Venkateswaran V; Sugar L; Loblaw A; Siminovitch K; Narod SA
    Clin Cancer Res; 2006 Nov; 12(21):6452-8. PubMed ID: 17085659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
    Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
    Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue.
    Magklara A; Scorilas A; Stephan C; Kristiansen GO; Hauptmann S; Jung K; Diamandis EP
    Urology; 2000 Sep; 56(3):527-32. PubMed ID: 10962338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.
    Mize GJ; Wang W; Takayama TK
    Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases.
    Chang MY; Seideman J; Sofou S
    Bioconjug Chem; 2008 Jun; 19(6):1274-82. PubMed ID: 18505278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
    Williams SA; Xu Y; De Marzo AM; Isaacs JT; Denmeade SR
    Prostate; 2010 May; 70(7):788-96. PubMed ID: 20058238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
    Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
    Ruigrok EAM; Tamborino G; de Blois E; Roobol SJ; Verkaik N; De Saint-Hubert M; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3627-3638. PubMed ID: 35556158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
    Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
    Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
    Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
    J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
    Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
    Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
    Siivola P; Pettersson K; Piironen T; Lövgren T; Lilja H; Bjartell A
    Urology; 2000 Oct; 56(4):682-8. PubMed ID: 11018639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells.
    Kumar A; Mikolajczyk SD; Hill TM; Millar LS; Saedi MS
    Prostate; 2000 Aug; 44(3):248-54. PubMed ID: 10906742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen.
    Black MH; Magklara A; Obiezu CV; Melegos DN; Diamandis EP
    Clin Chem; 1999 Jun; 45(6 Pt 1):790-9. PubMed ID: 10351987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.